The DRI Benzodiazepine enzyme immunoassay is a homogeneous assay intended for the qualitative and semi-quantitative determination of benzodiazepines in human urine.
The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay with liquid ready to-use reagents. The assay uses a specific antibody which can detect most benzodiazepines and their metabolites in urine. The assay is based on the competition of an enzyme glucose-6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, The enzyme-labeled drug is bound by the specific antibody and the enzyme activity is inhibited. This phenomenon creates a relationship between drug concentration in urine and the enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.